Democritus University of Thrace (DUTH)
Γενετικές παραλλαγές-πολυμορφισμοί των γονιδίων των Fcγ υποδοχέων: κλινικές και λειτουργικές επιπτώσεις στην εφαρμογή των μονοκλωνικών αντισωμάτων
Abstract
dc:descriptionPolymorphisms in FcγRIIα (CD32) and FcγRIIIα (CD16) receptors are associated with responses to the CD20 directed IgG1 monoclonal antibody rituximab among patients with indolent lymphoma. Rituximab is an important therapeutic for Waldenström’s macroglobulinemia (WM). The contribution of FcγRIIIα-158 polymorphisms, as well as at other positions, in response to rituximab has not been reported for WM. In these studies, we sequenced all coding regions of the FcγRIIIα from a series of 58 patients with WM to first define potential polymorphisms, and then correlated these findings to their response to rituximab. We observed single nucleotide variations in five codons of the FcγRIIα. Two were commonly observed and predicted for amino acid polymorphisms at FcγRIIIα-48: leucine/leucine (L/L), leucine/arginine (L/R), and leucine/histidine (L/H). Polymorphisms at FcγRIIIα-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). A clear linkage between these polymorphisms was detected and all patients with FcγRIIIα-158 F/F were always FcγRIIIα-48 L/L (p<.001). The response was significantly higher (p-0.03) for FcγRIIIα-158 V/V (40%) and V/F (35%) versus F/F (9%) supporting a primary role for FcγRIIIα-158 polymorphisms in predicting rituximab responses. Since polymorphisms in FcγRIIα-131 have been reported to influence rituximab responses, we performed directed sequencing of the genomic DNA coding region of FcγRIIα for 52 healthy individuals. Two common polymorphisms were observed for FcγRIIα (positions 27 and 131) and FcγRIIIα (positions 48 and 158). Importantly, we observed linkage among polymorphisms within and between FcγRIIα and FcγRIIIα, including the expression of histidine at FcγRIIα-131H and valine at FcγRIIIα-158V, both of which are associated with enhanced responses to rituximab. The results of these studies demonstrate that there is wide linkage within and between polymorphisms in FcγRIIα and FcγRIIIα, and may provide an explanation for why polymorphisms at FcγRIIα are associated with rituximab responses despite a lack of impact on IgG1 binding. The presence of valine (V) at FcγRIIIα-158 is shown to improve clinical response to rituximab in NHLS including WM. However, little is known about the basic mechanisms for this observation. We therefore sought to delineate differences in molecular and functional level among healthy individuals representing the three polymorphic groups (V/V, V/F and F/F). We observed higher levels of FcγRIIIα transcripts among individuals with FcγRIIIα-158 V/V versus V/F or F/F (p<0,001); increased cell-surface CD16 expression on NK-cells from individuals expressing at least one valine at FcγRIIIα-158 versus F/F (p-0.029), as well as augmented rituximab binding and rituximab-dependent ADCC activity. These results suggest that individuals expressing at least one V at FcγRIIIα-158 might, in part, have better clinical outcomes due to increased CD16 expression, rituximab binding, and rituximab-mediated ADCC.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Hatjiharissi, Evdoxia
- Χατζηχαρίση, Ευδοξία
Subjects
dc:subject × 18- Fcγ υποδοχείς
- Πολυμορφισμοί
- Μακροσφαιριναιμία Waldenstrom
- Ριτουξιμάμπη
- Υποδοχέας CD16
- Υποδοχέας CD32
- Αντι-CD20 μονοκλωνικά αντισώματα
- Fcγ receptors
- Polymorphisms
- Waldenstrom's macroglobulinemia
- Rituximab
- CD16 receptor
- CD32 receptor
- Anti-CD20 monoclonal antibodies
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/30411